Hagens Berman reminds Beta Bionics (NASDAQ: BBNX) investors of the November 3 lead plaintiff deadline in a securities class action. The suit alleges the company concealed FDA compliance issues, including an undisclosed Form 483 with over 18,000 unreported complaints, and made false statements about the iLet system. Shares fell 37% on January 8 after a miss on new patient starts, and further declined after a February 24 FDA Warning Letter.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
